We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Technopath Clinical Diagnostics

Technopath Clinical Diagnostics develops and manufactures total quality control (QC) solutions for clinical laborator... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
18 Mar 2021 - 21 Mar 2021
13 Apr 2021 - 16 Apr 2021

LGC Acquires Technopath Clinical Diagnostics to Strengthen Position in Clinical Diagnostics QC Market

By LabMedica International staff writers
Posted on 03 Feb 2021
Print article
LGC (Middlesex, UK) has acquired Technopath Clinical Diagnostics (Tipperary, Ireland), a developer and manufacturer of quality control (QC) solutions for clinical laboratories.

Technopath Clinical Diagnostics’ QC and software products are used by laboratories in over 120 countries globally. The acquisition augments LGC’s position in the clinical diagnostics QC market, complementing a wide breadth of existing manufacturing capabilities across calibration verification materials, molecular diagnostics and serology controls, clinical genomics reference materials and viral antigens.

“We are really excited to be bringing Technopath’s full-fledged chemistry and immunoassay controls into LGC,” said Euan O’Sullivan, President & Chief Operating Officer, LGC. “Their multi-constituent quality control products will dovetail perfectly with the calibration verification, molecular and serology product portfolios within our Clinical Diagnostics business unit. We look forward to combining Technopath’s and LGC’s expertise to deliver unrivalled solutions for our customers.”

“We are delighted to be joining LGC as an integral part of their fast-growing Clinical Diagnostics unit,” added Malcolm Bell, Chief Executive Officer, Technopath Clinical Diagnostics. “Technopath and LGC are an excellent fit as we share a purpose and mission, to support our customers by providing an expanded breadth of capability, geographic reach and scale. Our test consolidated multi analyte QC products allow end-customer labs to optimise their entire QC testing strategy while reducing waste and storage requirements and most importantly, reporting patient results with enhanced confidence and greater accuracy.”

Related Links:
Technopath Clinical Diagnostics

Gold Supplier
Blood Glucose Laboratory Analyzer
Nova Primary
COVID-19 IgM/IgG Test
DPP COVID-19 IgM/IgG System
Coronavirus Test
COVID-19 Coronavirus Real Time PCR Kit
Laboratory Automation Solution

Print article


Molecular Diagnostics

view channel
Image: Histopathologic image from a patient with Li Fraumeni syndrome showing accumulation of mutant TP53 in tumoral cells (Photo courtesy of Thierry Soussi, PhD).

Clinical Germline Testing Evaluated for Pediatric Cancer Patients

Pediatric cancer is rare, with fewer than 10,000 solid tumors diagnosed in children annually in the USA. Previous studies interrogating germline predisposition broadly across pediatric cancer types have... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.